Latest Rosetta Genomics Ltd. Stories
PHILADELPHIA and REHOVOT, Israel, July 6, 2011 /PRNewswire/ -- Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostic tests, today announced the effectiveness of a one-for-four reverse stock split of its share capital.
PHILADELPHIA and REHOVOT, Israel, May 9, 2011 /PRNewswire/ -- Rosetta Genomics (NASDAQ: ROSG) today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No.
PHILADELPHIA and REHOVOT, Israel, April 12, 2011 /PRNewswire/ -- Rosetta Genomics, Ltd. (Nasdaq: ROSG) today announced that the Company's Board of Directors has appointed Director Brian A.
MicroRNA-based Molecular Diagnostics to Mark Prometheus' Entry into Oncology Market; Rosetta to Receive Milestones and Research and Development Funding plus Future Royalties SAN DIEGO, PHILADELPHIA and REHOVOT, Israel, April 13 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, and Rosetta Genomics Ltd.
PHILADELPHIA, and REHOVOT Israel, February 12 /PRNewswire-FirstCall/ -- Rosetta Genomics Ltd. (Nasdaq:ROSG) reported today the first ever in-vivo efficacy data for a systemic microRNA-based cancer therapeutic.
PHILADELPHIA, Pennsylvania and REHOVOT Israel, January 16 /PRNewswire-FirstCall/ -- Rosetta Genomics Ltd.
REHOVOT, Israel and JERSEY CITY, New Jersey, January 8 /PRNewswire-FirstCall/ -- Rosetta Genomics, Ltd. (NASDQ: ROSG), the leading developer of microRNA-based molecular diagnostics, announced today it has signed an exclusive distribution agreement with Teva Pharmaceutical Industries Ltd.
- The deadly nightshade, Atropa Belladonna, which possesses stupefying or poisonous properties.
- A sleeping-potion; a soporific.
- To mutter deliriously.